Ten Companies Including Allist Pharmaceuticals and Yeasen Biotechnology Named Among Shanghai's First Batch of Innovative Enterprise Headquarters in Biopharma

Dec 11, 2023 17:34 CST Updated 17:34

Yeasen

Tool Enzyme Raw Materials and Diagnostic Product R&D, Manufacturer

Allist Pharmaceuticals

Innovative Drug Developer

United Imaging

High-end Medical Device Developer

Henlius

Innovative Biopharmaceutical Company

MedBot

Surgical Robot Developer

HeartCare

Neurointerventional Medical Device Developer

Medicilon

Preclinical Comprehensive R&D Services CRO

Click on the blue above"Medicine Valley"Follow Us

Recently, Allist Pharmaceuticals, Yeasen, and eight other companies have successfully been selected as part of the first batch of Shanghai's Innovative Enterprise Headquarters - Biomedical Field.

List of the First Batch of Shanghai Innovative Enterprise Headquarters (Biopharmaceuticals Field)

According toIt is understood that the headquarters of innovative enterprises awarded this time cover key industries such as integrated circuits, biomedicine, artificial intelligence, and digital economy, mainly presenting the following characteristics:

First, they have strong leadership. The awarded companies are mainly leading enterprises and technological innovation leaders in their respective industries. Over 90% of these companies’ products and services rank among the top in market share both in China and globally, holding a strong position and significant influence within their industries.

Second, they have strong innovation capabilities. The licensed companies invest heavily in R&D, with over 50% of them having launched either a Class I new drug or a product that is "first-of-its-kind" in China or even globally. Additionally, more than 10% of these companies have received national or municipal awards for scientific and technological progress.

Third, high growth potential. The licensed enterprises are all market players with good development momentum in recent years. Among them, 22 companies have been listed domestically and internationally in recent years, demonstrating strong development vitality. Over 60% of the enterprises have achieved a compound annual growth rate of more than 30% in revenue over the past three years, realizing rapid growth.

Fourth, the agglomeration development is evident. The regional agglomeration effect of the licensed enterprises aligns well with the strategic emerging industry cluster development positioning of each district.

Text | MedG